Skip to content

The effectiveness of Visual Schema Displacement Therapy in treating patients with PTSD.

The effectiveness of Visual Schema Displacement Therapy in treating patients with PTSD. - Effectiveness of VSDT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48388
Enrollment
57
Registered
2019-05-15
Start date
2019-09-11
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Interventions

The study has three conditions: EMDR, VSDT and a Waitlist control condition (WL). All patients will be randomly assigned to one of the three conditions. Both active interventions conist of six weekl

Sponsors

Universiteit Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - IQ > 80 (estimation) - PTSD diagnosis according tot he DSM-5 with one or more traumatic events. - Age: from 18 years - Sufficient command of the Dutch language

Exclusion criteria

Exclusion criteria: - Acutely suicidal patients - PTSD diagnosis not the primary diagnosis - Changes in medication prescription during, or 3 months prior to participation in the research - Use of strongly sedating medication.

Design outcomes

Primary

MeasureTime frame
The dependent variables are the presence of PTSD and the severity of the PTSD symptoms, respectively measured with the CAPS-5 and the PCL-5. Secondary outcome measures are depressive symptoms and general psychiatric symptoms, measured with the Beck Depression Inventory (BDI-II) and the Brief Symptom Inventory (BSI) respectively. The CAPS-5 will be conducted at the screening and at follow-up after one and three months. The PCL-5, BDI-II and the BSI will be measured weekly throughout the study.

Secondary

MeasureTime frame
Secondary outcome measures are depressive symptoms and general psychiatric symptoms, measured with the Beck Depression Inventory (BDI-II) and the Brief Symptom Inventory (BSI) respectively. These will be weekly conducted throughout the study.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)